Introduction　Pexidartinib,　an　oral　selective　colony-stimulating　factor　1　receptor　(CSF1R)　inhibitor,　is　the　only　systemic　therapy　approved　by　the　U.S.　Food　and　Drug　Administration　(FDA)　for　tenosynovial　giant　cell　tumor　(TGCT).　While　clinical　trials　have　defined　its　initial　safety　profile,　their　limited　sample　sizes　and　short　follow-up　restrict　the　detection　of　rare　or　delayed　adverse　events　(AEs),　underscoring　the　need　for　real-world　pharmacovigilance.Methods　Using　the　FDA　Adverse　Event　Reporting　System　(FAERS)　database,　we　conducted　a　disproportionality　analysis　to　characterize　the　post-approval　safety　profile　of　pexidartinib　and　identify　unlabeled　AEs,　applying　reporting　odds　ratio　(ROR),　proportional　reporting　ratio　(PRR),　Bayesian　confidence　propagation　neural　network　(BCPNN),　and　multi-item　gamma　Poisson　shrinker　(MGPS)　methods.Results　Among　7,168,342　FAERS　reports,　668　implicated　pexidartinib　as　the　primary　suspect,　with　AEs　reported　across　26　organ　systems.　Sixty-seven　preferred　terms　met　the　criteria　of　all　four　signal　detection　methods,　including　16　not　listed　in　the　FDA-approved　label.Discussion　The　overall　safety　profile　was　largely　consistent　with　clinical　trial　findings,　while　newly　detected　AEs　suggest　possible　rare　or　delayed　toxicities　in　broader　patient　populations.　These　results　highlight　the　importance　of　continuous　post-marketing　surveillance　and　support　the　need　for　prospective　studies　to　clarify　causal　relationships.